A recent study from the Department of Medical Genetics, Second Military Medical University, Shanghai, China shows that “lncRNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma.”
This study was published in the 12 May, 2014 issue of Cancer Cell (The number 1 journal in cancer biology with an IF of ~35) by Prof. Sun SH, Yuan JH and others from the Department of Medical Genetics, Second Military Medical University, Shanghai, China.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Anti-metastasis therapy for hepatocellular carcinoma: lncRNA-ATB suppresses the expression of p53 homolouge p73 via up regulation of its target gene . This study suggests, for the first time, that lncRNA-ATB, by up regulating its target genes, it may suppress the expression of tumor suppressor TAp73 and its downstream target genes. Thereby, it may accelerate invasion and metastasis. Together, this study suggests that pharmacological formulations encompassing “lncRNA-ATB suppressor or small molecule compounds that suppress the expression of lncRNA-ATB ” may be used to treat metastatic hepatocellular carcinoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan,L., Anti-metastasis therapy for hepatocellular carcinoma: lncRNA-ATB suppresses the expression of p53 homolouge p73 via up regulation of its target gene, Genome-2-Bio-Medicine Discovery center (GBMD), 26/08/2014, 13.51, http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation
Significance: Tumor suppressor p53 is mutated in most of the human tumors. However, its structural and functional homologues p73 and p63 are rarely mutated. lncRNA-ATB, by inducing the expression of its target gene, it may suppress the expression of p73. Based on these findings, this study suggests a therapeutic strategy as to how non-mutated p73 can be activated in mutant p53 expressing human cancers. That is, by inhibiting the expression of lncRNA-ATB in cancerous cells, one can activate TAp73. Thus, pharmacological formulations encompassing “lncRNA-ATB inhibitor“ may be used to treat mutant p53-expressing metastatic tumors, including hepatocellular carcinomas.